Follow Us
© 2026 Arizent. All rights reserved.
Nearly 60% of Americans who started taking weight-loss drugs between 2014 and 2023 didn’t continue long enough to see meaningful health benefits, according to a study of people covered by members of the Blue Cross Blue Shield.
About 30% of people who were prescribed the drugs stopped in the first month, according to data published in a report from the insurance company.
For reprint and licensing requests for this article, click here.
As healthcare expenses approach double-digit increases, employers are looking for savings in waste, care delivery, and plan administration before cutting benefits.
Employers face another steep rise in healthcare expenses in 2027, prompting a closer look at GLP-1 coverage, pharmacy spending and high-cost conditions.
As GLP-1 spending climbs, employers are asking whether the drugs deliver enough value. Better data could help them measure the payoff more accurately.
The potential for a healthier lifestyle is extending beyond medication to lifestyle and workplace habits that create change for employees.
Rising use of the weight-loss drug is fueling the fastest health plan cost growth in a decade and a half, forcing employers to rethink coverage strategies and cost management.
